Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Bibliographic record
Abstract
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials, deucravacitinib was superior to placebo and apremilast in patients with moderate to severe plaque psoriasis. This analysis evaluated deucravacitinib efficacy by baseline characteristics. Methods: Efficacy endpoints, including ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician’s Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1), were evaluated at Week 24 by baseline subgroups including weight, sex, and PASI in the pooled PSO-1 and PSO-2 population, and at Week 52 in PSO-1 patients who received continuous deucravacitinib treatment from Day 1. Results: In the pooled PSO-1 and PSO-2 population, deucravacitinib (n=843) was more efficacious than apremilast (n=422) at Week 24 across subgroups defined by baseline weight (<90 kg: PASI 75, 69.8% vs 43.8%, sPGA 0/1, 60.2% vs 34.2%; ≥90 kg: PASI 75, 55.4% vs 31.5%, sPGA 0/1, 45.9% vs 25.6%), sex (male: PASI 75, 59.3% vs 33.7%, sPGA 0/1, 49.6% vs 24.7%; female: PASI 75, 70.4% vs 45.2%, sPGA 0/1, 60.9% vs 39.4%), and PASI (≤20: PASI 75, 61.6% vs 38.6%, sPGA 0/1, 53.5% vs 32.4%; >20: PASI 75, 64.7% vs 37.0%, sPGA 0/1: 53.2% vs 27.1%). Consistent efficacy was observed through Week 52 in patients who received continuous deucravacitinib treatment in PSO-1 (n=332), regardless of baseline characteristics. Conclusion: Deucravacitinib demonstrated consistent efficacy for up to 52 weeks regardless of baseline characteristics in patients with moderate to severe plaque psoriasis. Acknowledgments This study was sponsored by Bristol Myers Squibb Writing and editorial assistance was provided by Liz Rockstein, PhD, of Peloton Advantage, LLC, an OPEN Health company, funded by Bristol Myers Squibb
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".